Induction of Covalent DNA Adducts in Rodents by Tamoxifen

Cancer Research

Volumn 52, Issue 5, 1992, Pages 1360-1363

  Han, Xueliang ^a   Liehr, Joachim G ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIESTROGEN; ASCORBIC ACID; DNA; TAMOXIFEN;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DNA ADDUCT; DNA MODIFICATION; ENDOMETRIUM CANCER; FEMALE; GENOTOXICITY; INTRAPERITONEAL DRUG ADMINISTRATION; ISOTOPE LABELING; KIDNEY CELL; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RAT; SYRIAN HAMSTER;

ACETYLCYSTEINE; ANIMAL; ASCORBIC ACID; DNA; FEMALE; HAMSTERS; KIDNEY; LIVER; PREMEDICATION; RATS; RATS, INBRED STRAINS; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN;

EID: 0026606580     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Riberio, G., and Swindell, R. The Christie Hospital adjuvant tamoxifen trial-status at 10 years. Br. J. Cancer, 57:601-603,1988.
2. Baum, M. Controlled trial of tamoxifen as single adjuvant agent in the management of early breast cancer analysis at six years by Nolvadex Adjuvant Trial Organization. Cancer (Phila.), 1:836-839,198S.
3. Anonymous. ODAC endorses tamoxifen trial, with modification to ensure enrollment of women at higher risk. Cancer Lett., 17 (No. 31); 1-3,1991.
4. Coezy, E., Borgna, J-L., and Rochefort, H. Tamoxifen and metabolites in MCF-cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res., 42:317-323, 1982.
5. Gottardis, M. M., and Jordan, V. C. Antitumor actions of keoxifene and tamoxifen in the JV-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res., 47:4020-4024,1987.
6. Wakeling, A. E., and Valcaccia, B. Antioestrogenic and antitumor activities of a series of non-steroidal antioestrogens. J. Endocrinol., 99:455-464,1983.
7. Liehr, J. G., Sirbasku, D. A., Jurka, E., Randerath, K., and Randerath, E. Inhibition of estrogen-induced renal carcinogenesis in male Syrian hamsters by tamoxifen without decrease in DNA adduct levels. Cancer Res., 48:779-783,1988.
8. Ward, H. W. C. Anti-oestrogen therapy for breast cancer a trial of tamoxifen at two dose levels. Br. Med. J., 1:13-14,1973.
9. Patterson, J. S., and Baum, M. Safety of tamoxifen. Lancet, 1:105,1978.
10. Reddy, M. V., Gupta, R. C., Randerath, E., and Randerath, K. 32P-postla-beling test for covalent DNA binding of chemicals in viva: application to a variety of aromatic carcinogens and methylating agents. Carcinogenesis (Lond.), 5:231-243,1984.
11. Reddy, M. V., and Randerath, K. Nuclease Pi-mediated enhancement of sensitivity of 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis (Lond.), 7: 1543-1551,1986.
12. Liehr, J. G., Roy, D., and Gladek, A. Mechanism of inhibition of estrogen-induced renal carcinogenesis in male Syrian hamsters by vitamin C. Carcinogenesis (Lond.), 10:1983-1988,1989.
13. DeFlora, S., Rossi, G. A., and DeFlora, A. Metabolic, desmutagenic and anticarcinogenic effects of JV-acetylcysteine. Respiration 50 (Suppl. 1); 43-49, 1986.
14. Liehr, J. G., and Wheeler, W. J. Inhibition of estrogen-induced renal carcinoma in Syrian hamsters by vitamin C. Cancer Res., 43:4638-4642,1983.
15. DeFlora, S., Astengo, M., Serra, D., and Bennicelli, C. Inhibition of urethane-induced lung tumors in mice by dietary JV-acetylcysteine. Cancer Lett., 32:235-241, 1986.
16. Lutz, W. K. Dose-response relationship and low dose extrapolation in chemical carcinogenesis. Carcinogenesis (Lond.), 11:1243-1247,1990.
17. Randerath, E., Miller, R. M., Mittal, D., Avitts, T. A., Dunsford, H. A., and Randerath, K. Covalent DNA damage in tissues of cigarette smokers as determined by 32P-postlabeling assay. J. Natl. Cancer Inst., 81: 341-347, 1989.
18. Gusberg, S. B. Tamoxifen for breast cancer associated endometrial cancer. Cancer (Phila.), 65:1463-1464,1990.
19. Mani, C., and Kupfer, D. Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res., 51:6052-6058,1991.
20. Meschter, C., Kendall, M., Rose, D., Jordan, K., and Williams, G. Carcinogenicity of tamoxifen. Toxicologist, 11: 190,1991.
21. Helgason, S., Wilking, N., Carlstrom, K., Damber, M-G., and von Schoultz, B. A comparative study of the estrogenic effects of tamoxifen and 17²-estradiol in postmenopausal women. J. Clin. Endocrinol. Metab., 54: 404-408,1982.